Gold prices steady amid Fed rate cut hopes; Trump-Putin talks awaited
Carlisle Companies Inc (NYSE:CSL (OTC:CSLLY)) stock has experienced a notable downturn, reaching a 52-week low of $315.2. Despite the recent decline, the company maintains a perfect Piotroski Score of 9, indicating strong financial health with a robust return on equity of 33% and healthy liquidity shown by a current ratio of 2.89. This latest price level reflects a significant retreat from better-performing times, as the company’s shares have seen a 1-year change with a decline of 20.67%. Investors are closely monitoring CSL’s performance, considering the broader economic context and industry-specific headwinds that have contributed to the stock’s downward pressure over the past year. The 52-week low serves as a critical point of interest for market watchers and shareholders alike, as they evaluate the company’s strategies for recovery and future growth. According to InvestingPro analysis, CSL appears undervalued at current levels, with 14 additional key insights available to subscribers, including detailed analysis of management’s share buyback program and dividend history.
In other recent news, Carlisle Companies reported its fourth-quarter 2024 earnings, revealing an adjusted earnings per share (EPS) of $4.47, which exceeded analyst expectations of $4.42. Despite this EPS beat, Carlisle’s revenue for the quarter was $1.1 billion, falling short of the forecasted $1.16 billion. The company’s full-year performance was strong, with a record adjusted EPS of $20.2, marking a 30% increase year-over-year, and a 9% increase in revenue driven by strategic initiatives. Looking ahead, Carlisle anticipates mid-single-digit consolidated revenue growth in 2025, with plans for $800 million in share buybacks and continued mergers and acquisitions (M&A) to enhance its product offerings.
In other company news, Esperion (NASDAQ:ESPR) Therapeutics has entered an exclusive license and distribution agreement with CSL Seqirus for the commercialization of its cholesterol-lowering drugs in Australia and New Zealand. Esperion will receive an upfront payment and is eligible for milestone payments totaling approximately $5 million. The agreement marks an expansion of Esperion’s global reach, as CSL Seqirus will handle regulatory approvals and marketing in these regions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.